Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy
NCT ID: NCT00524797
Last Updated: 2007-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life.
The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia.
This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Main
50 patients will receive Profonycia 5 gr/day PO for 7 days
Profonycia
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Profonycia
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ziv Hospital
OTHER_GOV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zidan Jamal, Prof
Role: PRINCIPAL_INVESTIGATOR
Ziv MC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oncology Unit, Ziv MC
Safed, , Israel
Oncology Unit
Safed, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Zidan Jamal, Prof
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zidan Jamal, Prof
Role: primary
Jamal Zidan, Prof
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Zidan J, Shetver L, Gershuny A, Abzah A, Tamam S, Stein M, Friedman E. Prevention of chemotherapy-induced neutropenia by special honey intake. Med Oncol. 2006;23(4):549-52. doi: 10.1385/MO:23:4:549.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP 7-260 S
Identifier Type: -
Identifier Source: org_study_id